Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Core Insights - Calidi Biotherapeutics has announced the issuance of a new patent for its SuperNova technology, enhancing its intellectual property portfolio and enabling the advancement of its CLD-201 program into clinical trials [1][3][8] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies, utilizing a novel stem cell-based platform to enhance the immune system's ability to fight cancer [10] - The company is headquartered in San Diego, California, and aims to address the unmet need for effective treatments of solid tumors [10] Technology and Innovation - The newly granted patent (U.S. Patent No. 12,036,278) covers methods and compositions related to cancer immunotherapy, specifically combining a smallpox vaccine with adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus [8][9] - The patent broadens previously allowed claims to include 21 smallpox vaccine virus strains, which supports the potential of the SuperNova platform to shield viral payloads from the immune system, enhancing delivery to tumor sites [9] Clinical Development - Calidi plans to submit an Investigational New Drug (IND) application to initiate its first-in-human clinical trial for the CLD-201 program, which is an off-the-shelf allogeneic therapy targeting advanced solid tumors [2][3] - The company has reported initial clinical success with its autologous adipose-derived stem cells loaded with vaccinia oncolytic viruses, indicating a promising path forward for its therapies [2]